Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Summary

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.

The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Conditions

• Psoriasis
• Atopic Dermatitis

Interventions

DEVICE

In situ cutaneous microdevice

The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. The microdevice will contain a subset of the following: Triamcinolone, 5-fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast.

DRUG

Triamcinolone

Triamcinolone

DRUG

5-Fluorouracil

5-fluorouracil

DRUG

Calcipotriene

Calcipotriene

DRUG

Tapinarof

Tapinarof

DRUG

Crisaborole

Crisaborole

DRUG

Tacrolimus

Tacrolimus

DRUG

Adalimumab

Adalimumab

DRUG

Etanercept

Etanercept

DRUG

Certolizumab

Certolizumab

DRUG

Infliximab

Infliximab

DRUG

Secukinumab

Secukinumab

DRUG

Ixekizumab

Ixekizumab

DRUG

Apremilast

Apremilast

DRUG

Risankizumab

Risankizumab

DRUG

Ustekinumab

Ustekinumab

DRUG

Hydroxychloroquine

Hydroxychloroquine

DRUG

Methotrexate

Methotrexate

DRUG

Mycophenolate

Mycophenolate

DRUG

Azathioprine

Azathioprine

DRUG

Chloroquine

Chloroquine

DRUG

Cyclosporine

Cyclosporine

DRUG

Tofacitinib

Tofacitinib

DRUG

Deucravacitinib

Deucravacitinib

DRUG

Dupilumab

Dupilumab

DRUG

Tralokinumab

Tralokinumab

DRUG

Guselkumab

Guselkumab

DRUG

Tildrakizumab

Tildrakizumab

DRUG

Baractinib

Baractinib

DRUG

Abrocitinib

Abrocitinib

DRUG

Upadacitinib

Upadacitinib

DRUG

Lebrikizumab

Lebrikizumab

DRUG

Nemolizumab

Nemolizumab

DRUG

Ruxolitinib

Ruxolitinib

DRUG

Bimekizumab

Bimekizumab

DRUG

Roflumilast

Roflumilast

Sponsors & Collaborators

• University of California, San Francisco

  lead OTHER

Principal Investigators

• Raymond Cho, MD, PhD · University of California, San Francisco

Study Design

Allocation

NA

Purpose

DEVICE_FEASIBILITY

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-01-01

Primary Completion

2030-06-01

Completion

2030-06-01

FDA Drug

Yes

Countries

• United States

Study Locations